Vireo Growth (VREOF) Cash from Operations (2020 - 2026)
Vireo Growth (VREOF) reported Cash from Operations of 11900000.0 for Q1 2026, up 450.0% on a YoY basis from 2163636.36 in Q1 2025, and down 36.21% sequentially from 18655743.0 in Q4 2025.
Vireo Growth (VREOF) Cash from Operations (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Cash from Operations data on file, last reported at 11900000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 450.0% year-over-year to 11900000.0; the trailing twelve-month figure through Mar 2026 stood at 19011491.0 (up 252.77% YoY), and the FY2025 full-year result was 3711491.0, up 136.26% from the prior year.
- Cash from Operations fell to 11900000.0 in Q1 2026, from 18655743.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 18655743.0 in Q4 2025 to a low of 6792823.0 in Q3 2025.
- A 5-year average of 803660.59 and a median of 2591374.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations plunged 49694.9% in 2025 and soared 450.0% in 2026, its largest moves.
- Tracing VREOF's Cash from Operations over 5 years: stood at 6119043.0 in 2022, then jumped by 92.49% to 459544.0 in 2023, then sank by 1302.11% to 6443302.0 in 2024, then surged by 389.54% to 18655743.0 in 2025, then sank by 36.21% to 11900000.0 in 2026.
- Business Quant data shows VREOF's Cash from Operations at 11900000.0 in Q1 2026, 18655743.0 in Q4 2025, and 6792823.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 11.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.90 Mn |
| Mar 31, 2026 | 11.90 Mn |
| Dec 31, 2025 | 18.66 Mn |
| Dec 31, 2025 | 18.66 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -4.75 Mn |
| Jun 30, 2025 | -4.75 Mn |
| Mar 31, 2025 | -3.40 Mn |
| Mar 31, 2025 | -3.40 Mn |
| Dec 31, 2024 | -6.44 Mn |
| Dec 31, 2024 | -6.44 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Jun 30, 2024 | -9,542.00 |
| Jun 30, 2024 | -9,542.00 |
| Mar 31, 2024 | -1.19 Mn |
| Mar 31, 2024 | -1.19 Mn |
| Dec 31, 2023 | -459,544.00 |
| Dec 31, 2023 | -459,544.00 |